Skip to main content
. 2020 Mar 31;7(5):541–548. doi: 10.1093/nop/npaa011

Fig. 2.

Fig. 2

Age-adjusted survival status for patients receiving concurrent radiation and temozolomide (N = 91). A Kaplan–Meier curve stratified by MetS status and adjusted for age at diagnosis depicts OS status, in months, for patients receiving concurrent radiation and temozolomide and adjuvant temozolomide. Patients with MetS had a significantly shorter median OS (12.4 mo, 95% CI: 9.5–14.2) compared with patients without MetS (17.9 mo, 95% CI: 15.0–22.1, P = 0.18).